Novartis' Ilaris wins FDA approval for juvenile arthritis

05/10/2013 | Reuters

Novartis obtained approval from the FDA to market Ilaris, or canakinumab, as a treatment for a serious form of childhood arthritis. Ilaris is an interleukin-1 beta inhibitor intended to be administered as a monthly subcutaneous injection.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC